PT - JOURNAL ARTICLE AU - Kyzar, Evan J. AU - Arbuckle, Melissa AU - Abba-Aji, Adam AU - Balachandra, Krishna AU - Cooper, Joseph AU - Dela Cruz, Adriane AU - Edens, Ellen AU - Heward, Brady AU - Jibson, Michael AU - Jordan, Ayana AU - Moreno-De-Luca, Daniel AU - Pazderka, Hannah AU - Singh, Mohit AU - Weleff, Jeremy AU - Yau, Bernice AU - Young, Justin AU - Ross, David A. AU - National Neuroscience Curriculum Initiative (NNCI) TI - Leveraging neuroscience education to address stigma related to opioid use disorder (OUD) in the community: A pilot study AID - 10.1101/2023.12.11.23299824 DP - 2023 Jan 01 TA - medRxiv PG - 2023.12.11.23299824 4099 - http://medrxiv.org/content/early/2023/12/13/2023.12.11.23299824.short 4100 - http://medrxiv.org/content/early/2023/12/13/2023.12.11.23299824.full AB - Opioid use disorder (OUD) and overdose deaths are a public health crisis. One contributing factor is stigma towards people who use opioids. We developed and conducted a public-facing, half-day educational event designed to challenge misperceptions about OUD from a contemporary neuroscience perspective. Participants engaged with three different resources on the neurobiology of addiction; at the end of the event, they rated its effectiveness. We also collected and compared pre- and post-event composite OUD stigma scales. Participants rated our approach and the overall event as highly effective. Additionally, OUD stigma scores were lower immediately following the event, and this decrease was primarily driven by decreased internalized stigma. Here, we demonstrate an effective proof-of-concept that an accessible, public-facing, neuroscience education event may reduce OUD stigma in the community.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe NNCI is funded in part by the Deeda Blair Research Initiative Fund for Disorders of the Brain through support to the Foundation for the National Institutes of Health, with additional funding from the Society of Biological Psychiatry (SOBP) and the American College of Neuropsychopharmacology (ACNP). EJK is supported by a training grant through the National Institute of Mental Health (R25 MH086466) and the Leon Levy Fellowship in Neuroscience. MA is supported by the above-named National Institute of Mental Health grant (R25 MH086466). AA-A is supported by grants from the New Frontiers in Research Fund, PRIHS-6, and Mitacs Accelerate fund. DM-D-L is supported by CASA Mental Health as the CASA Research Chair. DAR is supported by the Alberta Health Services Chair in Mental Health Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics Board of the University of Alberta gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors